Zentalis Pharmaceuticals (ZNTL)

Executive Summary

Zentalis Pharmaceuticals is a clinical-stage oncology company singularly focused on developing azenosertib, a first-in-class WEE1 inhibitor, for biomarker-defined cancers. The company is executing a late-stage, registration-focused strategy targeting Cyclin E1-positive platinum-resistant ovarian cancer, a population with profound unmet need and poor prognosis. Azenosertib is also being evaluated in multiple other indications, including breast cancer and pancreatic cancer, leveraging combinations with chemotherapy and immunotherapy to expand its therapeutic potential. The company's pipeline includes several active trials, with the most advanced being the Phase 2 DENALI trial in Cyclin E1-positive platinum-resistant ovarian cancer, which is fully enrolled and awaiting data readout.

Upcoming Catalysts (preview)

• Q3 2026Topline data from Phase 2 DENALI trial in Cyclin E1+ platinum-resistant ovarian cancer65% success
• Q4 2026Data update from Phase 1/2 trial of azenosertib + carboplatin + pembrolizumab in breast cancer (NCT06351332)50% success
• Q3 2026Regulatory update or FDA meeting regarding registration pathway for azenosertib70% success